Two concurrent new clinical trials will examine the feasibility of discontinuing the chronic therapies hypertonic saline or dornase alfa in patients with cystic fibrosis who have begun therapy with the elexacaftor/tezacaftor/ivacaftor (ETI) combination. The combination CF transmembrane regulator (CFTR) modulator therapy is set to greatly change the treatment of CF. Clinical trials showed it can ...
Can CFTR therapy SIMPLIFY the treatment burden in CF?
By Dave Levitan
2 Feb 2021